Should I buy or sell Aprea Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APRE shares. View APRE analyst ratings or view top-rated stocks .

What is Aprea Therapeutics' stock price target for 2024?

3 brokers have issued twelve-month price targets for Aprea Therapeutics' shares. Their APRE share price targets range from $9.00 to $20.00. On average, they anticipate the company's share price to reach $14.50 in the next year. This suggests a possible upside of 267.1% from the stock's current price. View analysts price targets for APRE or view top-rated stocks among Wall Street analysts .

How have APRE shares performed in 2023?

Aprea Therapeutics' stock was trading at $6.62 at the beginning of 2023. Since then, APRE stock has decreased by 40.3% and is now trading at $3.95. View the best growth stocks for 2023 here .

When is Aprea Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our APRE earnings forecast .

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics, Inc. (NASDAQ:APRE) posted its quarterly earnings data on Monday, November, 8th. The company reported ($9.00) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($9.00).

When did Aprea Therapeutics' stock split?

Aprea Therapeutics's stock reverse split before market open on Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV) , Brainstorm Cell Therapeutics (BCLI) , Biogen (BIIB) , Adaptimmune Therapeutics (ADAP) , Alector (ALEC) , Alkermes (ALKS) , Allogene Therapeutics (ALLO) , Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN) .

When did Aprea Therapeutics IPO?

(APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.

Who are Aprea Therapeutics' major shareholders?

Aprea Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Capital LLC (2.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Eyal C Attar , Gregory Alan Korbel and Lars B Abrahmsen . View institutional ownership trends .

How do I buy shares of Aprea Therapeutics?

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Aprea Therapeutics Stock Price, News & Analysis (NASDAQ:APRE)

$3.75

+0.06 (+1.63%)

(As of 02:31 PM ET)

Compare

Today's Range: $3.75
▼
$3.95
50-Day Range: $3.41
▼
$5.33
52-Week Range: $2.78
▼
$12.00

Volume: 1,937 shs
Average Volume: 22,826 shs
Market Capitalization: $14.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.50

Aprea Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 268.0% Upside
$14.50 Price Target
Short Interest: Healthy
3.70% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.07) to ($1.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

531st out of 935 stocks

Pharmaceutical Preparations Industry

247th out of 435 stocks

3.5

Analyst's Opinion

Consensus Rating
Aprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.50, Aprea Therapeutics has a forecasted upside of 268.0% from its current price of $3.94.
Amount of Analyst Coverage
Aprea Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.70% of the float of Aprea Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Aprea Therapeutics has a short interest ratio ("days to cover") of 9.4.
Change versus previous month
Short interest in Aprea Therapeutics has recently decreased by 3.26%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Aprea Therapeutics does not currently pay a dividend.
Dividend Growth
Aprea Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APRE.

2.7

News and Social Media Coverage

News Sentiment
Aprea Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Aprea Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for APRE on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.90% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 23.62% of the stock of Aprea Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Aprea Therapeutics are expected to grow in the coming year, from ($3.07) to ($1.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aprea Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aprea Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aprea Therapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aprea Therapeutics Stock (NASDAQ:APRE)

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

APRE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APRE Stock News Headlines

November 17, 2023 | markets.businessinsider.com

Capricor Therapeutics: Solid Financials and Promising DMD Trial Progression Support Buy Rating

November 12, 2023 | markets.businessinsider.com

VistaGen Therapeutics’ Robust Financial Position and Promising Pipeline Underpin Buy Rating: A Comprehensive Analysis

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 11, 2023 | markets.businessinsider.com

Promising Clinical Data and Financial Performance Validate Buy Rating for Aprea Therapeutics: An Analysis by Robert Driscoll

November 9, 2023 | msn.com

Aprea Therapeutics GAAP EPS of -$0.86

November 9, 2023 | finance.yahoo.com

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

October 16, 2023 | markets.businessinsider.com

Positive Outlook for Aprea Therapeutics: Promising Developments and Safety Profile of ATRN-119 Bolster Buy Rating

October 16, 2023 | finance.yahoo.com

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

October 6, 2023 | markets.businessinsider.com

Promising Outlook for Aprea Therapeutics: A Buy Rating Based on Upcoming Safety Data and Synthetic Lethal Targeting Potential

September 21, 2023 | markets.businessinsider.com

Aprea Therapeutics (APRE) Gets a Buy from Maxim Group

September 19, 2023 | finance.yahoo.com

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 11, 2023 | finance.yahoo.com

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

September 6, 2023 | finance.yahoo.com

Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 24, 2023 | finance.yahoo.com

Myelodysplastic Syndrome Drugs Global Market Report 2023

August 24, 2023 | finance.yahoo.com

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

August 10, 2023 | finance.yahoo.com

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

August 1, 2023 | seekingalpha.com

RLFTF Relief Therapeutics Holding AG

June 14, 2023 | finance.yahoo.com

Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference

May 30, 2023 | finance.yahoo.com

Aprea Therapeutics to Present at BIO International Convention

May 17, 2023 | msn.com

HC Wainwright & Co. Reiterates Aprea Therapeutics (APRE) Buy Recommendation

May 11, 2023 | marketwatch.com

Global Targeting p53 Cancer Therapies Market Size 2023-2031 Competitive Landscape by Absolute Reports | with [86 Pages]

May 8, 2023 | finance.yahoo.com

Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

April 24, 2023 | finance.yahoo.com

Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now

April 1, 2023 | markets.businessinsider.com

Maxim Group Sticks to Their Buy Rating for Aprea Therapeutics (APRE)

March 31, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Aprea Therapeutics (APRE)

March 31, 2023 | msn.com

Aprea Therapeutics GAAP EPS of -$0.92 beats by $2.30

See More Headlines

Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APRE
CUSIP: N/A
CIK: 1781983
Web: www.aprea.com
Phone: 617-463-9385
Fax: N/A
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.50
High Stock Price Target: $20.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +268.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,660,000.00
Net Margins: N/A
Pretax Margin: -2,330.88%
Return on Equity: -55.45%
Return on Assets: -45.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.15
Quick Ratio: 6.15

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.66 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 3,740,000
Free Float: 2,956,000
Market Cap: $14.74 million
Optionable: Not Optionable
Beta: 0.77

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Oren Gilad Ph.D. (Age 54)
Co-Founder, CEO, President and Director
Comp: $520.84k
Mr. John P. Hamill CPA (Age 59)
Senior VP, CFO, Principal Accounting Officer & Secretary
Dr. Dansu Li Ph.D.
Head of Technology
Dr. Lars B. Abrahmsen Ph.D. (Age 66)
Senior VP & Chief Scientific Officer
Dr. Michel Afargan Ph.D.
Head of Pharmacology Development
Mr. Ze'ev Weiss B.Sc. (Age 61)
C.P.A., Chief Business Advisor
Ms. Andrea Epstein
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Aprea Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APRE shares.
View APRE analyst ratings or view top-rated stocks.
What is Aprea Therapeutics' stock price target for 2024?: 3 brokers have issued twelve-month price targets for Aprea Therapeutics' shares. Their APRE share price targets range from $9.00 to $20.00. On average, they anticipate the company's share price to reach $14.50 in the next year. This suggests a possible upside of 267.1% from the stock's current price.
View analysts price targets for APRE or view top-rated stocks among Wall Street analysts.
How have APRE shares performed in 2023?: Aprea Therapeutics' stock was trading at $6.62 at the beginning of 2023. Since then, APRE stock has decreased by 40.3% and is now trading at $3.95.
View the best growth stocks for 2023 here.
When is Aprea Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our APRE earnings forecast.
How were Aprea Therapeutics' earnings last quarter?: Aprea Therapeutics, Inc. (NASDAQ:APRE) posted its quarterly earnings data on Monday, November, 8th. The company reported ($9.00) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($9.00).
When did Aprea Therapeutics' stock split?: Aprea Therapeutics's stock reverse split before market open on Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aprea Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN).
When did Aprea Therapeutics IPO?: (APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.
Who are Aprea Therapeutics' major shareholders?: Aprea Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Capital LLC (2.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Eyal C Attar, Gregory Alan Korbel and Lars B Abrahmsen.
View institutional ownership trends.
How do I buy shares of Aprea Therapeutics?: Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:APRE) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial